Astrana Health, Inc. (NASDAQ:ASTH) Receives Average Recommendation of “Moderate Buy” from Analysts

Astrana Health, Inc. (NASDAQ:ASTH) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $53.2857.

Separately, Zacks Research cut Astrana Health from a “strong-buy” rating to a “strong sell” rating in a report on Monday, September 1st.

Astrana Health Stock Performance

Shares of ASTH opened at $29.68 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $1.66 billion, a price-to-earnings ratio of 58.20, a PEG ratio of 0.74 and a beta of 0.85. The stock has a 50 day moving average of $27.76 and a 200 day moving average of $27.95. Astrana Health has a 12 month low of $21.20 and a 12 month high of $63.20.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.36 by ($0.17). The company had revenue of $654.81 million during the quarter, compared to the consensus estimate of $639.13 million. Astrana Health had a return on equity of 3.43% and a net margin of 1.04%.Astrana Health’s revenue was up 34.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.40 earnings per share. Astrana Health has set its Q3 2025 guidance at EPS. As a group, sell-side analysts forecast that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Trading of Astrana Health

Institutional investors have recently added to or reduced their stakes in the company. Covestor Ltd lifted its stake in Astrana Health by 777.6% in the first quarter. Covestor Ltd now owns 2,001 shares of the company’s stock worth $62,000 after purchasing an additional 1,773 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $115,000 after purchasing an additional 3,517 shares during the last quarter. AlphaQuest LLC grew its holdings in shares of Astrana Health by 144.2% during the first quarter. AlphaQuest LLC now owns 4,883 shares of the company’s stock valued at $151,000 after buying an additional 2,883 shares during the last quarter. State of Wyoming purchased a new stake in shares of Astrana Health during the second quarter valued at $132,000. Finally, US Bancorp DE lifted its position in Astrana Health by 21.3% during the first quarter. US Bancorp DE now owns 5,791 shares of the company’s stock valued at $180,000 after purchasing an additional 1,015 shares during the period. Institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.